20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T9651 | PD-1/PD-L1-IN-9 | PD-1/PD-L1 | |
PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in... | |||
T9616 | PD-1/PD-L1-IN-10 | PD-1/PD-L1 | |
PD-1/PD-L1-IN-10 is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy. | |||
T3655 | BMS-1 | PD1-PDL1 inhibitor 1,PD-1/PD-L1 inhibitor 1 | Apoptosis , PD-1/PD-L1 |
BMS-1 (PD-1/PD-L1 inhibitor 1) is an inhibitor of the PD1-PD-L1 protein-protein interaction. It also acts as an immunomodulator. Programmed death ligand 1 (PD-L1) is a protein in humans that is encoded by the CD274 gene ... | |||
T36900 | PD-1/PD-L1-IN-NP19 | PD-1/PD-L1-IN-NP19 | PD-1/PD-L1 |
PD-1/PD-L1-IN-NP19, a PD-1/PD-L1 inhibitor, exhibits an IC50 of 12.5 nM against the human PD-1/PD-L1 interaction, potentially activating the tumor immune microenvironment and contributing to its antitumor effects[1]. | |||
T40112 | PROTAC PD-1/PD-L1 degrader-1 | PROTAC PD-1/PD-L1 degrader-1 | |
PROTAC PD-1/PD-L1 degrader-1, a Cereblon E3 ligand-based compound, is a PD-1/PD-L1 PROTAC that effectively inhibits the interaction between PD-1 and PD-L1 with an IC50 value of 39.2 nM. It successfully restores the suppr... | |||
T36899 | INCB086550 | PD-1/PD-L1-IN-8 | PD-1/PD-L1 |
INCB086550 (PD-1/PD-L1-IN-8) (example 24) is a PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. | |||
T39591 | Human PD-L1 inhibitor I | Human PD-L1 inhibitor I | |
Human PD-L1 inhibitor I is a peptide ligand that specifically inhibits the interaction between human PD-L1 and human PD-1. It exhibits a KD value of 3.39 μM, indicating its binding affinity. The presence of Human PD-L1 i... | |||
T36487 | Evixapodlin | PD-1/PD-L1-IN 7,GS-4224 | Antiviral , HBV , PD-1/PD-L1 |
Evixapodlin (PD-1/PD-L1-IN 7) is a human PD-1/PD-L1 protein/protein interaction inhibitor (IC50: 0.213).Evixapodlin has anticancer and antiviral activities. | |||
T39589 | Human PD-L1 inhibitor III | Human PD-L1 inhibitor III | |
Human PD-L1 inhibitor III is a human PD-L1 inhibitor. | |||
T39590 | Human PD-L1 inhibitor II | Human PD-L1 inhibitor II | |
Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity. | |||
T39588 | Human PD-L1 inhibitor IV | Human PD-L1 inhibitor IV | |
Human PD-L1 inhibitor IV is a polypeptide compound that competitively inhibits the human PD-1 protein. It has a Kd value of 1.38 μM and effectively blocks the interaction between hPD-1 and hPD-L1. | |||
T12380 | PD-1/PD-L1-IN 5 TFA | PD-1/PD-L1-IN 5 | Others |
PD-1/PD-L1-IN 5 is an inhibitor of PD-1/PD-L1 protein/protein interaction (IC50 of ≤100 nM). | |||
T3146 | BMS-202 | PD1-PDL1 inhibitor 2,PD-1/PD-L1 inhibitor 2 | Apoptosis , PD-1/PD-L1 |
BMS-202 (PD1-PDL1 inhibitor 2) is an inhibitor of the PD-1 (Programmed death- 1) /PD-Ll (Programmed death-ligand 1) protein/protein interaction. | |||
T4696 | BMS202 hydrochloride (1675203-84-5(free base)) | PD-1/PD-L1 inhibitor 2 hydrochloride | PD-1/PD-L1 |
BMS202 hydrochloride (1675203-84-5(free base)) (PD-1/PD-L1 inhibitor 2 hydrochloride) is a small-molecule PD-1/PD-L1 interaction inhibitor (IC50: 18 nM). Biophysical studies demonstrate that BMS202 binds directly to PD-L... | |||
T26859 | BMS-8 | PD-1/PD-L1 | |
BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers. | |||
TP1463 | PD-1/PD-L1-IN 3 TFA (1629654-95-0 free base) | PD-1/PD-L1-IN 3 TFA | |
PD-1/PD-L1-IN 3 TFA inhibits the binding of human PD-1 to PD-Ll with an IC50 of 9 nM. | |||
T72670 | PD-1/PD-L1-IN-13 | ||
PD-1/PD-L1-IN-13 is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC50 value of 10.2 nM for PD-1/PD- L1 interaction.PD-1/PD-L1-IN-13 promotes CD8+ T-cell activation and delays tumour growth in a Hepa1-6 homozyg... | |||
T62501 | PD-1/PD-L1-IN-17 | ||
PD-1/PD-L1-IN-17 (Compound P20) is a potent PD-1/PD-L1 inhibitor (IC50: 26.8 nM). PD-1/PD-L1-IN-17 is a promising lead compound for the development of inhibitors of PD-1/PD-L1 interactions. -17 has potential for cancer d... | |||
T72675 | PD-1/PD-L1-IN-23 | ||
PD-1/PD-L1-IN-23 is a potent, orally active ester prodrug of L7, a benzooxadiazole derivative, and functions as an inhibitor of PD-1/PD-L1. It has been biologically evaluated for its inhibitory effects on PD-L1, demonstr... | |||
T63614 | PD-1/PD-L1-IN-15 | ||
PD-1/PD-L1-IN-15 is a potent inhibitor of PD-1/PD-L1 (IC50: 60.1 nM) and has shown investigational potential for tumor immunotherapy. |